Session Type: ePosters
Session Title: ePosters
Authors(s): C. Sigera (1), C. Rodrigo (2), N.L. De Silva (3), P. Weeratunga (4), S.D. Fernando (1), S. Rajapakse (4)
Authors Affiliations(s): (1) Department of Parasitology, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka, (2) Department of Pathology, School of Medical Sciences, UNSW Sydney, 2052, NSW, Australia, Australia, (3) Department of Clinical Medicine, Faculty of Medicine, Sir John Kotelawala Defence University, Ratmalana, Sri Lanka, Sri Lanka, (4) Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka
Background:
The cost in managing hospitalised dengue patients vary across countries depending on access to healthcare, management guidelines, availability of diagnostic tests and state sponsored subsidies. Hence for health budget planning and cost reduction, locally relevant, accurate costing data from prospective studies, is essential. A comprehensive, recent analysis of costs associated with monitoring Sri Lankan dengue patients in hospitals is unavailable except for few limited datasets (less than 150 patients).
Methods:Colombo Dengue Study (CDS) is a prospective single centre cohort study in Sri Lanka that recruits hospitalised dengue patients in the first three days of fever and follows them up until death / discharge. The diagnosis of dengue is retrospectively confirmed and therefore the cohort also have non-dengue fever patients with a phenotypically similar illness, managed as dengue while in hospital. The direct costs of hospital admission (base and investigation costs, excluding medication) were calculated for all recruited patients and compared between dengue (DF) and non-dengue fever (NDF) patients as well as other subgroups based on demographic, clinical or temporal characteristics.
Results:Over 29 months, a total of 431 (males – 285, 66.1%, mean age: 31.4 years) confirmed DF patients and 256 NDF patients (males –176, 68.8%, mean age: 37.7 years) were recruited between October 2017 to February 2020. The standardised hospitalisation costs were USD 18.02 (SD: 4.42) and USD 17.55 (SD: 4.09) per patient per day for DF and NDF patients respectively. There was no significant difference of daily cost or for the cost of total stay (based on the average duration of stay) between these groups (p>0.05). Investigations accounted for more than 50% of the total cost. The costs were also largely homogenous in all subgroups within or across DF and NDF categories.
Conclusions:
This single centre prospective study conducted over two and half years (2017 – 2020) demonstrates NDF patients incur the same cost as DF patients, investing in better diagnostic services may lead to overall cost savings through early confirmation and less intensive monitoring of NDF patients. The costs were largely homogenous across different subgroups based on demographic, clinical and temporal characteristics.
Keyword(s): Cost, Dengue, Diagnostic testsCOI Institutional Grants: Yes
Session Type: ePosters
Session Title: ePosters
Authors(s): C. Sigera (1), C. Rodrigo (2), N.L. De Silva (3), P. Weeratunga (4), S.D. Fernando (1), S. Rajapakse (4)
Authors Affiliations(s): (1) Department of Parasitology, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka, (2) Department of Pathology, School of Medical Sciences, UNSW Sydney, 2052, NSW, Australia, Australia, (3) Department of Clinical Medicine, Faculty of Medicine, Sir John Kotelawala Defence University, Ratmalana, Sri Lanka, Sri Lanka, (4) Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Sri Lanka, Sri Lanka
Background:
The cost in managing hospitalised dengue patients vary across countries depending on access to healthcare, management guidelines, availability of diagnostic tests and state sponsored subsidies. Hence for health budget planning and cost reduction, locally relevant, accurate costing data from prospective studies, is essential. A comprehensive, recent analysis of costs associated with monitoring Sri Lankan dengue patients in hospitals is unavailable except for few limited datasets (less than 150 patients).
Methods:Colombo Dengue Study (CDS) is a prospective single centre cohort study in Sri Lanka that recruits hospitalised dengue patients in the first three days of fever and follows them up until death / discharge. The diagnosis of dengue is retrospectively confirmed and therefore the cohort also have non-dengue fever patients with a phenotypically similar illness, managed as dengue while in hospital. The direct costs of hospital admission (base and investigation costs, excluding medication) were calculated for all recruited patients and compared between dengue (DF) and non-dengue fever (NDF) patients as well as other subgroups based on demographic, clinical or temporal characteristics.
Results:Over 29 months, a total of 431 (males – 285, 66.1%, mean age: 31.4 years) confirmed DF patients and 256 NDF patients (males –176, 68.8%, mean age: 37.7 years) were recruited between October 2017 to February 2020. The standardised hospitalisation costs were USD 18.02 (SD: 4.42) and USD 17.55 (SD: 4.09) per patient per day for DF and NDF patients respectively. There was no significant difference of daily cost or for the cost of total stay (based on the average duration of stay) between these groups (p>0.05). Investigations accounted for more than 50% of the total cost. The costs were also largely homogenous in all subgroups within or across DF and NDF categories.
Conclusions:
This single centre prospective study conducted over two and half years (2017 – 2020) demonstrates NDF patients incur the same cost as DF patients, investing in better diagnostic services may lead to overall cost savings through early confirmation and less intensive monitoring of NDF patients. The costs were largely homogenous across different subgroups based on demographic, clinical and temporal characteristics.
Keyword(s): Cost, Dengue, Diagnostic testsCOI Institutional Grants: Yes